THE EFFECTIVENESS OF CLOPIDOGREL AS AN ANTITHROMBOTIC COMPARED TO TICLOPIDINE AND ASPIRIN (META-ANALYSIS)

Titien Siwi Hartayu(1*), Dewi Setyaningsih(2),

(1) Fakultas Farmasi, Universitas Sanata Dharma, Kampus III Maguwoharjo Depok Sleman, Yogyakarta 55282, Indonesia
(2) Fakultas Farmasi, Universitas Sanata Dharma, Kampus III Maguwoharjo Depok Sleman, Yogyakarta 55282, Indonesia
(*) Corresponding Author

Abstract


Clopidogrel, an antithrombotic drug, has been proven by FDA as Plavix was initially used for the prevention of vascular occlusive that cause of myocardial infarction, stroke, and vascular death in patients with atherosclerosis and then it is used to treat Acute Coronary Syndrome (ACS). Aim of the study is to compare the effectiveness of Clopidogrel to aspirin and ticlopidine by meta-analysis of CLASSICS (The Clopidogrel Aspirin Stent International Cooperative Study), MATCH trial dan CAPRIE trial. Results of the study show that the effectiveness of Clopidogrel is significantly higher, however the risk of ischemic and bleeding is lower than aspirin and ticlopidine. Cost-effectiveness of Clopidogrel in avoiding secondary stroke in one episode is approximately US $ 33,000, and aspirin is only US $ 1400. In Indonesia the price of Clopidogrel is ranged from US $1.5 to US $3 each tablet, while the price of aspirin ranged from US $ 0.35 to US $ 0.72. However, in Indonesia Clopidogrel is now in the list of National Formulary, this fact might have contributed to the increasing use of Clopidogrel, which has reached around 1000 tablets per day in each hospital while aspirin has reached almost 1500 tablets per day.

Keywords


antithrombotic; aspirin; antiplatelet; Clopidogrel; ticlopidine

Full Text:

PDF

References


Algra, A., Gijn, J.v., 2000. Is clopidogrel superior to aspirin in secondary prevention of vascular disease? Curr Control Trials Cardiovasc, 1, 143-145.

Amarenco, P., Donnan, G. A., 2004. Should the MATCH results be extrapolated to all stroke patients and affect ongoing trials evaluating clopidogrel plus aspirin? Stroke, 35(11), 2606-2608.

Aschenbrenner, D. S., Price, C., 2007. A new indication for clopidogrel. AJN, 107(2), 35.

Bertrand, M. E., Rupprecht, H.J., Urban, P., Gershlick, A. H., 2000. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. Circulation, 102, 624-629.

Bhatt, D., Marso, S., Hirsch, A., Ringleb, P.A., Hacke, W., Topol, E.J., 2002. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol, 90, 625-628.

Bhatt, D. L., Bertrand, M. E., Berger, P.B., L'Allier, P.L., Moussa, I., Moses, J.W., Dangas, G., Taniuchi, M., Lasala, J.M., Holmes, D.R., Ellis, S.G., Topol, E.J., 2002. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol, 39(1), 9-14.

Braunwald, E., Antman, E. M., Beasly, J.W., Califf, R.M., Cheitlin, M.D., Hochman, J.S. et al., 2002. ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and NonST-Segment Elevation Myocardial Infarction-2002; Summary Article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Unstable Angina). Circulation, 106, 1893-1900.

Commitee, C. S., 1996. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 348(9038), 1329-1339.

Diener, H. C., 2002. Aspirin therapy should be first-line treatment in secondary prevention of stroke--against. Stroke, 33(8), 2138-2139.

Donnan, G.A., Davis, S.M., 2002. Aspirin therapy should be first line: probably, but watch this space. Stroke, 33(8), 2139-2140.

Durand-Zaleski, I., Bertrand, M., 2004. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. Pharmacoeconimic, 22(suppl 4), 19-27.

Garattini, S., Bertele, V., 2004. Risk: Benefit Assessment of Old Medicines. Br J Clin Pharmacol, 58(6), 581-586.

Gebel, J.M., Jr., 2005. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view. J Am Coll Cardiol, 46(5), 752-755.

Hankey, G.J., 2005. Is clopidogrel the antiplatelet drug of choice for high-risk patients with stroke/TIA?: No. J Thromb Haemost, 3(6), 1137-1140.

Harker, L.A., Marzec, U.M., Kelly, A.B., Chronos, N.R., Sundell, I.B., Hanson, S.R., et al., 1998. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation, 98, 2461-2469.

Herbert, J.M., Dol, F., Bernart, A., Falotico, R., Lale, A., Savi, P., 1998. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost, 80, 512-518.

Herbert, J., Tissinier, A., Defreyn, G., Maffrand, J., 1993. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation following arterial injury in rabbits. Arterioscler Thromb, 13, 1171-1179.

Makkar, R., Eigler, N., Kaul, S., Frimerman, A., Nakamura, M., Shah, P., et al., 1998. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. European Heart Journal, 19, 1538-1546.

Mueller, C., Roskamm, H., Neumann, F.J., Hunziker, P., Marsch, S., Perruchoud, A., et al. 2003. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. Journal of the American College of Cardiology, 41(6), 969-973.

NHS, 2004. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome Technology Appraisal 80. National Institute for Clinical Excellence, 1-24.

Niessen L.W., Dippel, D.W., Limburg, M., 2000. Calculation of costs of stroke, cost effectiveness of stroke units and secondary prevention in patients after a stroke, as recommended by revised CBO practice guideline 'Stroke'. Ned Tijdschr Geneeskd, 144(41 abstract), 1959-1964.

Philips, D.R., Conley, P.B., Sinha, U., Andre, P., 2005. Therapeutic approaches in arterial thrombosis. J.of throm & Haem, 3, 1577-1589.

Ringleb, P.A., Bhatt, D.L., Hirsch, A., Topol, E.J., Hacke, W., et al, 2004. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke, 35, 528-532.

Sado, D., 2001. Drug Discovery. Student BMJ, 3, 13-15.

Sharis, P., Cannon, C., Loscalzo, J., 1998. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med, 129, 394-405.

Steinhubl, S.R., Tan, W.A., Foody, J. M., Topol, E.J., 1999. Incidence and clinical course of thrombotic thrombocytopenic purpurea due to ticlopidine following coronary stenting. JAMA, 281(9), 806-810.

Tran, H., Anand, S.S., 2004. Oral Antiplatelet Therapy in Cerebrovascular Disease, Coronary Artery Disease, and Peripheral Arterial Disease. JAMA, 292(15), 1867-1874.

Warlow, C., 2002. Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke. Stroke, 33(8), 2137-2138.

Weitz, J., Hirsh, J., 1998. New antothrombotic agents. Chest, 114(5), 715S-727S.

Yeghiazarians, Y., Braunstein, J., Askari, A., Stone, P., 2000. Unstable angina pectoris. N Engl J Med, 342, 101-114.




DOI: https://doi.org/10.24071/jpsc.00565

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 Journal of Pharmaceutical Sciences and Community

 

 

 

 

 

 

 

  

Jurnal Farmasi Sains dan Komunitas (Journal of Pharmaceutical Sciences and Community)

Published by Faculty of Pharmacy, Universitas Sanata Dharma Yogyakarta

Creative Commons Licence
This work is licensed under a Creative Commons Attribution 4.0 International License.